Neulasta and Nplate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Neulasta (pegfilgrastim) and Nplate (romiplostim). Common drug interactions include lymphoma among females and myelodysplastic syndrome among males.

The phase IV clinical study analyzes what interactions people have when they take Neulasta and Nplate. It is created by eHealthMe based on reports of 75 people who take the same drugs from the FDA, and is updated regularly.

What is Neulasta?

Neulasta has active ingredients of pegfilgrastim. It is often used in agranulocytosis. eHealthMe is studying from 92,286 Neulasta users. Check the latest studies of Neulasta.

What is Nplate?

Nplate has active ingredients of romiplostim. It is often used in idiopathic thrombocytopenic purpura (itp). eHealthMe is studying from 17,850 Nplate users. Check the latest studies of Nplate.



On Jul, 10, 2026

75 people who take Neulasta and Nplate together, and have interactions are studied.

Neulasta and Nplate drug interactions.

What are the common drug interactions of Neulasta and Nplate, by gender? *:

female:

  1. Lymphoma (cancer that begins in immune system cells)
  2. Bone pain
  3. Injection site discolouration
  4. Death
  5. Drug ineffective
  6. Abscess fungal (pus produced by a fungal infection)
  7. Candidiasis (candidiasis or thrush is a fungal infection)
  8. Enterococcal infection
  9. Haematuria (presence of blood in urine)
  10. Hepatic neoplasm malignant (liver cancer)

male:

  1. Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)
  2. Neoplasm malignant (cancer tumour)
  3. Jugular vein thrombosis (clot in jugular vein)
  4. Myelitis (infection or the inflammation of white matter or gray matter of spinal cord which is a part of central nervous system)
  5. Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system)
  6. Orthostatic hypotension (a medical condition consisting of a sudden decrease in blood pressure when a person stands up)
  7. Anaemia (lack of blood)
  8. Benign prostatic hyperplasia (benign enlargement of the prostate)
  9. Bone marrow failure
  10. Enterocolitis infectious

What are the common drug interactions of Neulasta and Nplate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Nausea (feeling of having an urge to vomit)
  2. Arthralgia (joint pain)
  3. Burning sensation
  4. Oedema peripheral (superficial swelling)
  5. Pulmonary embolism (blockage of the main artery of the lung)
  6. Constipation
  7. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  8. Anxiety
  9. Asthenia (weakness)
  10. Back pain

50-59:

  1. Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)
  2. Bone pain
  3. Injection site discolouration
  4. Abscess fungal (pus produced by a fungal infection)
  5. Candidiasis (candidiasis or thrush is a fungal infection)
  6. Enterococcal infection
  7. Haematuria (presence of blood in urine)
  8. Hepatic neoplasm malignant (liver cancer)
  9. Hyperglycaemia (high blood sugar)
  10. Hypoaesthesia (reduced sense of touch or sensation)

60+:

  1. Neoplasm malignant (cancer tumour)
  2. Death
  3. Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)
  4. Neurotoxicity (when the exposure to natural or artificial toxic substances, which are called neurotoxins, alters the normal activity of the nervous system)
  5. Orthostatic hypotension (a medical condition consisting of a sudden decrease in blood pressure when a person stands up)
  6. Anaemia (lack of blood)
  7. Asthenia (weakness)
  8. Benign prostatic hyperplasia (benign enlargement of the prostate)
  9. Bone marrow failure
  10. Enterocolitis infectious

What are the existing conditions these people have? *

  1. Idiopathic Thrombocytopenic Purpura (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting): 30 people, 40.00%
  2. Anaemia (lack of blood): 6 people, 8.00%
  3. Anaemia Of Malignant Disease: 4 people, 5.33%

* Approximation only. Some reports may have incomplete information.

Do you take Neulasta and Nplate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Neulasta and Nplate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Neulasta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Nplate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Neulasta and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Nplate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on pegfilgrastim and romiplostim (the active ingredients of Neulasta and Nplate, respectively), and Neulasta and Nplate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: